1. 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. (December 2022) Authors: Baramidze, A.; Gogishvili, M.; Melkadze, T.; Giorgadze, D.; Penkov, K.D.; Makharadze, T.; Kalinka, E.; Nechaeva, M.; Laktionov, K.; Gessner, C.; Moreno Jaime, B.; Passalacqua, R.; Garassino, M.C.; Li, S.; Pouliot, J-F.; McGuire, K.; Quek, R.G.; Kaul, M.; Gullo, G.; Rietschel, P. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗